Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – CNS tumours

3553 - Association of systemic inflammation with local tumor characteristics and survival in glioma patients

Date

28 Sep 2019

Session

Poster Discussion – CNS tumours

Presenters

Pegah Mir Seyed Nazari

Citation

Annals of Oncology (2019) 30 (suppl_5): v143-v158. 10.1093/annonc/mdz243

Authors

P. Mir Seyed Nazari1, C. Ay1, M. Preusser2, J. Riedl1, C. Marosi2, F. Moik1, G. Ricken3, J.A. Hainfellner3, I. Pabinger-Fasching1, A.S. Berghoff2

Author affiliations

  • 1 Clinical Division Of Hematology And Hemostaseology, Medical University of Vienna, 1090 - Vienna/AT
  • 2 Division Of Oncology, Medical University of Vienna, 1090 - Vienna/AT
  • 3 Institute Of Neurology, Medical University of Vienna, 1090 - Vienna/AT

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3553

Background

Immunotherapy has yield only modest clinical efficacy in glioma so far. However, gliomas are characterized by a range of immune suppressive features. Here, we aimed to analyze the correlation of systemic inflammation with local tumor characteristics and overall survival in glioma patients.

Methods

Glioma patients were recruited at time of diagnosis or recurrence within the Vienna Cancer and Thrombosis Study (CATS). At study inclusion, a blood draw was performed. IDH1 mutation, PD-L1 and podoplanin in glioma were assessed via immunohistochemistry.

Results

193 glioma patients (4.7% diffuse glioma, 19.7% anaplastic glioma, 75.6% glioblastoma) were included. IDH1 mutation was present in 40/193 (20.7%) patients, PD-L1 expression was observed in 20/193 (10.4%) patients, and podoplanin positivity was found in 134/193 (69.4%) patients. IDH1 mutation was associated with higher platelet count (median: 303 vs. 232 G/L, p = 0.001) and lower neutrophil count (4.71 vs 6.55 G/L, p = 0.021) as well as lower neutrophil/lymphocyte (N/L) ratio (3.34 vs. 5.13, p = 0.016). PD-L1 was associated with higher monocyte count (0.657 vs. 0.450 G/L, p = 0.008), higher C-reactive protein (CRP) (0.43 vs. 0.1 mg/dL, p = 0.005) and higher fibrinogen (379 vs. 303 mg/dL, p = 0.001). Podoplanin was associated with higher leukocyte count (8.88 vs 7.22 G/L, p = 0.040), higher neutrophil count (6.44 vs 5.03 G/L, p = 0.048), higher N/L ratio (5.4 vs. 3.2, p = 0.006) and lower platelet count (227 vs 289 G/L, p < 0.0001). Upon multivariable adjustment for sex and age, platelet count (hazard ratio per 1 unit increase: 0.997, 95% CI [0.995-0.999], p = 0.006), leukocyte count (1.040 [1.004-1.077], p = 0.030), neutrophil count (1.043 [1.000-1-087], p = 0.049) and CRP levels (1.095 [1.010-1-187], p = 0.027) correlated with overall survival.

Conclusions

Systemic inflammation correlated with overall survival in the present glioma cohort. Furthermore, molecular glioma characteristics (IDH1 mutation, PD-L1, podoplanin) were linked to distinct systemic inflammation patterns. Clinical trials on immune modulating therapies should consider these different glioma-immune system interactions in order to potentially select patients with the highest benefit.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Medial University of Vienna.

Funding

Austrian National Bank.

Disclosure

P. Mir Seyed Nazari: Travel / Accommodation / Expenses: Bayer. M. Preusser: Research grant / Funding (self): Böhringer-Ingelheim; Research grant / Funding (self): GlaxoSmithKline; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Merck Sharp & Dome; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Roche; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Gerson Lehrman Group (GLG); Honoraria (self), Advisory / Consultancy: CMC Contrast; Honoraria (self), Advisory / Consultancy: GlaxoSmithKline,; Honoraria (self), Advisory / Consultancy: Mundipharma; Honoraria (self), Advisory / Consultancy: Astra; Honoraria (self), Advisory / Consultancy: Zeneca; Honoraria (self), Advisory / Consultancy: AbbVie; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Medahead; Honoraria (self), Advisory / Consultancy: Daiichi Sankyo. A.S. Berghoff: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Daiichi Sankyo; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy: Bristol-Meyers Squibb; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: AbbVie. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.